Hikma Pharmaceuticals Plc - Company Profile
Powered by 
All the data and insights you need on Hikma Pharmaceuticals Plc in one report.
$295
- Save hours of research time and resources with
our up-to-date Hikma Pharmaceuticals Plc Strategy Report
- Understand Hikma Pharmaceuticals Plc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Hikma Pharmaceuticals Plc Catalyst Calendar
Proactively evaluate Hikma Pharmaceuticals Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Hikma Pharmaceuticals Plc Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 05 Feb 2023 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 01 Aug 2022 | Phase IV Trial Initiation | Hikma Pharmaceuticals LLC | - | imatinib mesylate | Oncology | Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) | Clinical Trial Registry |
| 10 Feb 2022 | Phase I Trial Initiation | Hikma Pharmaceuticals Plc; International Pharmaceutical Research Center; Invitro Research Solutions Pvt Ltd | HIK | cladribine | Central Nervous System | Multiple Sclerosis; Relapsing Multiple Sclerosis (RMS) | Clinical Trial Registry |
| 01 Jan 2021 | Phase IV Trial Initiation | Hikma Pharmaceuticals Plc | HIK | Sclera | Central Nervous System | Relapsing Remitting Multiple Sclerosis (RRMS) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer